Product Unit size Cat. code Docs. Price


Monoclonal dog IgG2 antibody against dog CD20

Show product

100 µg


This antibody has been removed from our catalog. However, you may contact us if you wish to order minimal quantities.

Monoclonal dog IgG2 antibody against dog CD20

Anti-dCD20c1-dIgG2 is a chimeric monoclonal antibody specific for dog CD20 (dCD20). TIn flow cytometry applications, this antibody has exhibited weak cross-reactivity with human CD20. Reactivity with other species has not been tested.

It has been produced in CHO cells and purified by affinity chromatography with protein A.

Anti-dCD20c1-dIgG2 was generated by combining the constant domains of the dog IgG2 molecule with the variable regions of Anti-dCD20c1-mIgG2a.

Anti-dCD20c1-mIgG2a has been selected for its ability to bind dCD20 and induce complement-dependent cytotoxicity (CDC).

Back to the top


Clonality: Monoclonal antibody

Specificity: Targets cells expressing dog CD20

Isotype: Dog IgG2, kappa

Clone: 6C12

Formulation: 0.2 µm filtered solution in 68 mM phosphate buffer with 91 mM glycine, 5% w/v saccharose and stabilizing agents

Quality control:

  • The absence of bacterial contamination (e.g. endotoxins and peptidoglycans) is confirmed by using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.
  • Recognition of dCD20 with this antibody is tested using flow cytometry.

Applications: Flow cytometry, cell lysis, B-cell depletion

Not suitable for immunohistochemical staining.

Back to the top


100 µg purified anti-dCD20c1-dIgG2 antibody, provided azide- free and lyophilized.

Product is shipped at room temperature.

Store lyophilized antibody at -20°C.

Back to the top


CD20 is a transmembrane phosphoprotein that is expressed on the surface of malignant and normal B lymphocytes.

As CD20 expression is restricted to B cells, this antigen is a useful marker or target for B-cell lymphomas [1].
Studies demonstrate that the expression of CD20 correlates with B-cell lymphoma in dogs [2]. In human medicine, an anti-human CD20 monoclonal antibody (Rituximab) has been approved by the FDA to treat B-cell non-Hodgkin's lymphoma resistant to other chemotherapy regimens.

Binding of rituximab to CD20 results in cell destruction through different mechanisms including direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity. Rituximab was tested for B-cell binding and depletion in canine B-cells ex vivo; however, this human therapeutic is not able to bind or deplete canine B-cells [3, 4]. Thus, there is a need for specific antibodies directed against dog CD20.

Such antibodies can be used to investigate CD20 as a therapeutic target in canine lymphoma.


1. Kosmas C. et al., 2002. Anti-CD20-based therapy of B cell lymphoma: state of the art. Leukemia. 16(10):2004-15.
2. Jubala C. et al., 2005. CD20 Expression in Normal Canine B Cells and in Canine non-Hodgkin Lymphoma. Vet. Path. 42:468-76.
3. Crow S., 2008. Chemoimmunotherapy for canine lymphoma: tumor vaccines and monoclonal antibodies. Cancer Therapy 6;181-6.
4. Impellizeri J. et al., 2006. The role of rituximab in the treatment of canine lymphoma: An ex vivo evaluation. Vet. J. 171:556-8.
5. Rütgen B. et al., 2010. Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma. Leuk Res. 4(7):932-8.

Back to the top
Customer Service
& Technical Support
Shopping cart is empty